A Blood-Based Biomarker Panel For Stratifying Current Risk For Colorectal Cancer DELETE UJ

UTSePress Research/Manakin Repository

Search UTSePress Research


Advanced Search

Browse

My Account

Show simple item record

dc.contributor.author Marshall, K W en_US
dc.contributor.author El Khettabi, F en_US
dc.contributor.author Nossova, N en_US
dc.contributor.author Chao, S en_US
dc.contributor.author Bao, W S en_US
dc.contributor.author Ma, J. en_US
dc.contributor.author Li, X J en_US
dc.contributor.author Liew, C C en_US
dc.contributor.editor en_US
dc.date.accessioned 2012-02-02T11:13:27Z
dc.date.available 2012-02-02T11:13:27Z
dc.date.issued 2010 en_US
dc.identifier 2010005293 en_US
dc.identifier.citation Marshall K W et al. 2010, 'A Blood-Based Biomarker Panel For Stratifying Current Risk For Colorectal Cancer DELETE UJ', International Journal of Cancer, John Wiley & Sons Inc, Hoboken en_US
dc.identifier.issn 0020-7136 en_US
dc.identifier.other C2 en_US
dc.identifier.uri http://hdl.handle.net/10453/16787
dc.description.abstract Colorectal cancer (CRC) is often curable and preventable using current screening modalities. Unfortunately, screening compliance remains low, partly due to patient dissatisfaction with faecal/endoscopic testing. Recent guidelines advise CRC screening should begin with risk stratification. A blood-based test providing clinically actionable CRC risk information would likely improve screening compliance and enhance clinical decision making. We analyzed 196 gene expression profiles to select candidate CRC biomarkers. qRT-PCR was performed on 642 samples to develop a 7-gene biomarker panel using 112 CRC/120 controls (training set) and 202 CRC/208 controls (independent, blind test set). Panel performance characteristics and disease prevalence (0.7%) were then used to develop a scale assessing an individual?s current risk of having CRC based on his/her gene signature. A 7-gene panel (ANXA3, CLEC4D, LMNB1, PRRG4, TNFAIP6, VNN1 and IL2RB) discriminated CRC in the training set (area under the receiver-operating-characteristic curve (ROC AUC), 0.80; accuracy, 73%; sensitivity, 82%; specificity 64%). The independent blind test set confirmed performance (ROC AUC, 0.80; accuracy, 71%; sensitivity, 72%; specificity, 70%). Individual gene profiles were compared against the population results and used to calculate the current relative risk for CRC. We have developed a 7-gene, blood-based biomarker panel that can stratify subjects according to their current relative risk across a broad range in an average-risk population. Across the continuous spectrum of risk as defined by the current relative risk scale, it is possible to identify clinically meaningful reference points that can assist patients and physicians in CRC screening decision making. en_US
dc.language en_US
dc.publisher John Wiley & Sons Inc en_US
dc.relation.isbasedon http://dx.doi.org/10.1002/ijc.24910 en_US
dc.title A Blood-Based Biomarker Panel For Stratifying Current Risk For Colorectal Cancer DELETE UJ en_US
dc.parent International Journal of Cancer en_US
dc.journal.volume 126 en_US
dc.journal.number 5 en_US
dc.publocation Hoboken en_US
dc.identifier.startpage 1177 en_US
dc.identifier.endpage 1186 en_US
dc.cauo.name DVCRch.Institute for Sustainable Futures en_US
dc.conference Verified OK en_US
dc.for 111200 en_US
dc.personcode 0000070639 en_US
dc.personcode 0000070640 en_US
dc.personcode 0000070641 en_US
dc.personcode 0000070642 en_US
dc.personcode 0000070643 en_US
dc.personcode 0000045570 en_US
dc.personcode 0000070644 en_US
dc.personcode 0000070645 en_US
dc.percentage 100 en_US
dc.classification.name Oncology and Carcinogenesis en_US
dc.classification.type FOR-08 en_US
dc.edition en_US
dc.custom en_US
dc.date.activity en_US
dc.location.activity en_US
dc.description.keywords colorectal cancer, biomarkers, blood test, disease risk, stratification en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record